Vice Chair, Department of Urologic Surgery
To see if Marc A. Dall'Era is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Dr. Dall’Era specializes in the management of malignant disease of the urinary tract.
The specialty care Dr. Dall’Era offers includes:
Dr. Dall'Era's research interests include active surveillance for prostate cancer including utilization of mp-MRI and biomarker discovery and validation. He is also involved in translational research for urothelial cancer diagnosis and management including advanced genomics analysis of bladder tumors.
B.S., UC Davis, Davis CA 1995
M.D., UC Davis, Davis CA 2000
General Surgery, University of Washington, Seattle WA 2000-2001
Urology, University of Washington, Seattle WA 2001-2005
Oncology, UC San Francisco, San Francisco CA 2006-2008
Dall'Era, MA, Klotz, L. Active surveillance for intermediate-risk prostate cancer. Prostate Cancer and Prostatic Diseases. 2017;20(1):1-6.
Yap, SA, Yuh, LM, Evans, CP, Dall'Era, MA, Wagenaar, RM, Cress, R, Lara, PN. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World Journal of Urology. 2017;35(2):277-283.
Pugashetti, N, Chandrasekar,T, Lurvey, R, Durbin-Johnson, B, Dall'Era, M, de Vere White, R, Evans, C, Yap, S. Perioperative Outcomes Following Neoadjuvant Chemotherapy and Radical Cystectomy-Is There Room for Improvement? Urology Practice Journal. 2016;3:364-370.
Pan, A, Zhang, H, Li, Y, Lin, T, Wang, F, Lee, J, Cheng, M, Dall'Era, M, Li, T, de Vere White, R, Pan, C, Lam, K. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016;27(42): 1-9.
Chandrasekar, T, Pugashetti, N, Durbin-Johnson, B, Dall'Era, MA, Evans, CP, de Vere White, RW, Yap, SA. Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? Bladder cancer (Amsterdam, Netherlands). 2016;2(4): 441-448.
Chow, H, Ghosh, PM, de Vere White, R, Evans, CP, Dall'Era, MA, Yap, SA, Li, Y, Beckett, LA, Lara, PN, Pan, CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016;122(12):1897-904.
Marc A. Dall'Era, Benjamin J. Davies. Clinical Case Discussion: Intermediate-Risk Prostate Cancer: The Case for Active Surveillance. European Urology Focus. 2015;1(2):208-209.
Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, Denes BS. Utility of the Oncotype DX Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A retrospective Chart Review Analysis. Urology Practice. 2015;2:343-348.
Yuh L, Dall’Era MA, Penson DF, Evan CP. Active Surveillance for Prostate Cancer Under the Patient Protection and Affordable Act. Urology Practice. 2015;2(4):154-159.
Pugashetti N, Yap SA, Lara PN, Gandour-Edwards R, Dall’Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Canadian Urological Association Journal. 2015;9(3-4):E204-207.